Iris Energy Limited vs uniQure N.V. Ordinary Shares — how do they compare? Iris Energy Limited trades at $29.92 (market cap $13.71B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Iris Energy Limited is far larger — about 9.3× uniQure N.V. Ordinary Shares's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Iris Energy Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IREN | QURE | |
|---|---|---|
Market Cap | $13.71B | $1.48B |
Volume | 50,877,922 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $76.41 | $70.59 |
52-Week Low | $29.31 | $9.03 |
Typical Hold Time | 28 Days | 0 Days |
Enterprise Value | $15.66B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals despite bullish oscillators, with key support at $34. Recent earnings misses and a negative net income margin of -99.38% highlight financial strain, though revenue grew to $501M in 2025. Analyst sentiment remains strongly positive with a consensus price target of $81.00, driven by the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA.
The outlook is bifurcated: substantial upside exists if IREN executes its AI transition, but high valuation ratios and persistent losses pose risks. Investors should weigh the aggressive growth projections against current profitability challenges and capital intensity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →